 |
Current Controversies in Biologic Therapy for Crohn's Disease: Debating the Application of Emerging Clinical Data to Daily Treatment Decisions CME William J. Sandborn, MD, Moderator; Remo Panaccione, MD, FRCPC; Uma Mahadevan-Velayos, MD; Brian G. Feagan, MD Author Information and Disclosures Release Date: January 10, 2008; Valid for credit through January 10, 2009 | Physicians - maximum of 2.0 AMA PRA Category 1 Credit(s)™ for physicians | | This CME activity is based on transcripts and slides of presentations as delivered by the faculty at the "Current Controversies in Biologic Therapy for Crohn's Disease: Debating the Application of Emerging Clinical Data to Daily Treatment Decisions" symposium held at the Philadelphia Marriott in Philadelphia, Pennsylvania, on October, 14, 2007.
To participate in this activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details. Contents of This CME Activity- Welcome and IntroductionWilliam J. Sandborn, MDAvailable As: Slides/Audio | Slides/Transcript | Audio
Should Biologic Agents Be Used Routinely as Monotherapy for Patients With CD?
- Monotherapy Is PreferredRemo Panaccione, MD, FRCPCAvailable As: Slides/Audio | Slides/Transcript | Audio
- The Case for Combination TherapyBrian G. Feagan, MDAvailable As: Slides/Audio | Slides/Transcript | Audio
To Switch or Not to Switch: What Are the Options for the Patient Who Develops an Attenuated Response or Intolerance to a Biologic Agent?
- The Case for SwitchingBrian G. Feagan, MDAvailable As: Slides/Audio | Slides/Transcript | Audio
- Optimizing Before Switching: Burning Bridges Is Not a Good IdeaUma Mahadevan-Velayos, MDAvailable As: Slides/Audio | Slides/Transcript | Audio
Does the Risk of Ineffective Treatment of CD Outweigh the Potential Adverse Events Associated With Aggressive Therapy? Assessing the Benefit/Risk Equation for Conventional and Biologic Agents
- The Step-Up ApproachUma Mahadevan-Velayos, MDAvailable As: Slides/Audio | Slides/Transcript | Audio
- The Top-Down ApproachRemo Panaccione, MD, FRCPCAvailable As: Slides/Audio | Slides/Transcript | Audio
- Question and Answer SessionWilliam J. Sandborn, MD, Remo Panaccione, MD, FRCPC,
Uma Mahadevan-Velayos, MD, Brian G. Feagan, MDAvailable As: Slides/Audio | Slides/Transcript | Audio
Legal DisclaimerThe material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. Copyright © 2008 Scientific Frontiers, Inc. |
|
|
Learning Objectives Upon completion of this activity, participants should be able to: - Describe the latest clinical data demonstrating the efficacy and safety of biologic agents for the induction and maintenance of clinical remission in CD, including
avoidance of hospitalization and surgery, steroid withdrawal, and fistula healing.
- Compare the benefits and risks associated with early, aggressive treatment of CD using either conventional or biologic therapy vs the poor long-term prognosis associated with suboptimal therapy for CD.
- Describe the therapeutic options for CD patients who develop an attenuated response or intolerance to an initial biologic agent, including switching to another
biologic agent that targets the same or a different molecular pathway.
- Assess the role of biologic monotherapy, without the use of concomitant immunomodulators, for patients with CD, taking into account efficacy and safety considerations.
Author Disclosures Brian G. Feagan,
MD
Disclosure: Grant/Research Support, Consultant, Advisory Board, Speakers' Bureau: Abbott Laboratories, AstraZeneca, Berlex, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene Corp., Celltech, Centocor, CombinatoRx, Elan/Biogen, ISIS Pharmaceuticals Inc., Janssen-Ortho Inc., Millennium Pharmaceuticals Inc., Napo Pharmaceuticals, Novartis, Osiris Therapeutics Inc., Otsuka America, Procter & Gamble Pharmaceuticals, Protein Design Laboratories,
Santarus Inc., Schering Canada, Schering-Plough, Synta Pharmaceuticals, Teva Pharmaceuticals, Tillotts Pharma, UCB Pharma Uma Mahadevan-Velayos, MD
Disclosure: Consultant, Speakers' Bureau: Abbott Laboratories, Axcan, Centocor, Elan Pharmaceuticals, Procter & Gamble Pharmaceuticals, Protein Design Laboratories, UCB Pharma Remo Panaccione, MD, FRCPC
Disclosure: Grant/Research Support, Consultant, Advisory Board, Speakers' Bureau: Abbott Laboratories, AstraZeneca, Axcan, Bristol-Myers Squibb, Byk Solvay, Centocor, Elan Pharmaceuticals, Ferring, GlaxoSmithKline, Janssen, Millennium Pharmaceuticals Inc., Procter & Gamble Pharmaceuticals, Prometheus Laboratories, Schering-Plough, Shire Pharmaceuticals, UCB Pharma William J. Sandborn, MD
Disclosure:
Grant/Research Support, Consultant, Advisory Board: Abbott Laboratories, Centocor, Elan Pharmaceuticals, Procter & Gamble Pharmaceuticals, Prometheus Laboratories, Shire Pharmaceuticals, UCB Pharma Disclosures of Program Planners
Eric P. Gall, MD
(Chicago Medical School)
Consultant, Speaker's Bureau – Amgen, Merck, Novartis.
Sy Schlager,
MD, PhD
(Scientific Frontiers, Inc.)
No financial interests/relationships with financial interest relating to the topic of this activity. Jointly sponsored by Chicago Medical School at Rosalind Franklin University of Medicine and Science and Scientific Frontiers, Inc.
|
 |
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Rosalind Franklin University of Medicine and Science and Scientific Frontiers, Inc. Rosalind Franklin University of Medicine and Science is accredited by the ACCME to provide continuing medical education for physicians.
Rosalind Franklin University of Medicine & Science designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Contact This Provider
|
|
